IDORSIA LTD |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.249 CHF | -1.36% |
|
+10.40% | +7.47% |
| Jul. 01 | New semester, new state of mind |  |
| Jul. 01 | Idorsia Wins European Commission's Nod for Resistant Hypertension Treatment | MT |
| Sales 2024 * | 105M 116M | Sales 2025 * | 206M 228M | Capitalization | 410M 453M |
|---|---|---|---|---|---|
| Net income 2024 * | -380M -420M | Net income 2025 * | -356M -393M | EV / Sales 2024 * | 13.8 x |
| Net Debt 2024 * | 1.05B 1.16B | Net Debt 2025 * | 1.21B 1.34B | EV / Sales 2025 * | 7.87 x |
| P/E ratio 2024 * |
-1.55
x | P/E ratio 2025 * |
-1.99
x | Employees | 650 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | +8.57% | ||
| 1 week | +12.32% | ||
| Current month | +12.54% | ||
| 1 month | -12.10% | ||
| 3 months | -4.12% | ||
| 6 months | +7.85% | ||
| Current year | +7.85% |
1 week
2.01
2.42
1 month
1.962.70
Current year
1.293.70
1 year
1.297.24
3 years
1.2926.00
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
André Muller
CEO | Chief Executive Officer | 60 | 17-05-31 |
Jean-Paul Clozel
CHM | Chairman | 69 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CHM | Chairman | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 775 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 2.272 | -0.35% | 20 982 |
| 24-07-02 | 2.28 | +8.57% | 878,228 |
| 24-07-01 | 2.1 | +3.65% | 750,726 |
| 24-06-28 | 2.026 | -1.17% | 385,013 |
| 24-06-27 | 2.05 | -0.39% | 348,713 |
Delayed Quote Swiss Exchange, July 02, 2024 at 11:30 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-07-25
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.28
CHF
Average target price
1.692
CHF
Spread / Average Target
-25.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.85% | 454M | |
| +16.44% | 122B | |
| +18.94% | 113B | |
| +18.92% | 26.22B | |
| -25.37% | 19.01B | |
| -20.21% | 15.71B | |
| -20.20% | 15.22B | |
| -47.37% | 14.72B | |
| +59.91% | 14.58B | |
| +4.35% | 13.84B |
- Stock Market
- Equities
- IDIA Stock
